Price Alert

Puma Biotechnology Inc. (PBYI)

NASDAQ: PBYI · Real-Time Price · USD

5.63

0.31 (5.83%)

At close: Aug 15, 2025, 12:28 PM

Puma Biotechnology Statistics

Share Statistics

Puma Biotechnology has 49.64M shares outstanding. The number of shares has increased by 1.21% in one year.

Shares Outstanding	49.64M
Shares Change (YoY)	1.21%
Shares Change (QoQ)	0.06%
Owned by Institutions (%)	61.32%
Shares Floating	37.93M
Failed to Deliver (FTD) Shares	3,261
FTD / Avg. Volume	0.77%

Short Selling Information

The latest short interest is 2.61M, so 5.25% of the outstanding shares have been sold short.

Short Interest	2.61M
Short % of Shares Out	5.25%
Short % of Float	6.15%
Short Ratio (days to cover)	7.65

Valuation Ratios

The PE ratio is 4.9 and the forward PE ratio is 15.98. Puma Biotechnology's PEG ratio is 0.14.

PE Ratio	4.9
Forward PE	15.98
PS Ratio	0.64
Forward PS	1.1
PB Ratio	1.61
P/FCF Ratio	3.82
PEG Ratio	0.14

Financial Ratio History

Enterprise Valuation

Puma Biotechnology has an Enterprise Value (EV) of 153.24M.

EV / Sales	0.66
EV / EBITDA	3.19
EV / EBIT	3.94
EV / FCF	3.94

Financial Position

The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.8.

Current Ratio	1.54
Quick Ratio	1.45
Debt / Equity	0.8
Debt / EBITDA	1.54
Debt / FCF	1.91
Interest Coverage	2.49

Financial Efficiency

Return on Equity is 32.87% and Return on Invested Capital is 23.14%.

Return on Equity	32.87%
Return on Assets	14.19%
Return on Invested Capital	23.14%
Revenue Per Employee	$1.34M
Profits Per Employee	$176.03K
Employee Count	172
Asset Turnover	1.08
Inventory Turnover	7.38

Taxes

Income Tax	-6.18M
Effective Tax Rate	-25.63%

Stock Price Statistics

The stock price has increased by 39.77% in the last 52 weeks. The beta is 1.29, so Puma Biotechnology's price volatility has been higher than the market average.

Beta	1.29
52-Week Price Change	39.77%
50-Day Moving Average	3.41
200-Day Moving Average	3.14
Relative Strength Index (RSI)	65.9
Average Volume (20 Days)	423,725

Income Statement

In the last 12 months, Puma Biotechnology had revenue of 230.47M and earned 30.28M in profits. Earnings per share was 0.62.

Revenue	230.47M
Gross Profit	166.06M
Operating Income	30.97M
Net Income	30.28M
EBITDA	48.08M
EBIT	36.55M
Earnings Per Share (EPS)	0.62

Full Income Statement

Balance Sheet

The company has 69.22M in cash and 74.08M in debt, giving a net cash position of -4.86M.

Cash & Cash Equivalents	69.22M
Total Debt	74.08M
Net Cash	-4.86M
Retained Earnings	-1.31B
Total Assets	196.18M
Working Capital	45.85M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 38.92M and capital expenditures -56K, giving a free cash flow of 38.86M.

Operating Cash Flow	38.92M
Capital Expenditures	-56K
Free Cash Flow	38.86M
FCF Per Share	0.8

Full Cash Flow Statement

Margins

Gross margin is 72.06%, with operating and profit margins of 13.44% and 13.14%.

Gross Margin	72.06%
Operating Margin	13.44%
Pretax Margin	10.46%
Profit Margin	13.14%
EBITDA Margin	20.86%
EBIT Margin	13.44%
FCF Margin	16.86%

Dividends & Yields

PBYI does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	20.41%
FCF Yield	26.19%

Dividend Details

Analyst Forecast

The average price target for PBYI is $7, which is 44.3% higher than the current price. The consensus rating is "Buy".

Price Target	$7
Price Target Difference	44.3%
Analyst Consensus	Buy
Analyst Count	1

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	5.15
Graham Upside	6.19%

Scores

Altman Z-Score	-6.08
Piotroski F-Score	7